Evidence map›Paper›PMID 35274720›Full record

ArticleThe oncologist2022

Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer.

Meredith N Freeman, Albert Jang, Jason Zhu, Farhad Sanati, Lakshminarayanan Nandagopal, Deepak Ravindranathan, Arpita Desai, Audrey Phone, Roberto Nussenzveig, Ellen Jaeger and 9 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Meredith N FreemanTulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA.
Albert JangTulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA.
Jason ZhuLevine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Farhad SanatiUniversity Hospitals Seidman Cancer Center, Cleveland, OH, USA.
Lakshminarayanan NandagopalUniversity of Alabama at Birmingham, Birmingham, AL, USA.
Deepak RavindranathanWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Arpita DesaiUniversity of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Audrey PhoneUniversity of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Roberto NussenzveigHuntsman Cancer Institute-University of Utah Health Care, Salt Lake City, UT, USA.
Ellen JaegerTulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA.
Sydney A CaputoTulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA.
Vadim S KoshkinUniversity of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Umang SwamiHuntsman Cancer Institute-University of Utah Health Care, Salt Lake City, UT, USA.
Arnab BasuUniversity of Alabama at Birmingham, Birmingham, AL, USA.
Mehmet A BilenWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Neeraj AgarwalHuntsman Cancer Institute-University of Utah Health Care, Salt Lake City, UT, USA.
Oliver SartorTulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA.
Earle F BurgessLevine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Pedro C BarataTulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA.ORCID 0000-0002-8890-2951

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe outcomes of metastatic hormone-sensitive prostate cancer (mHSPC) have significantly improved through treatment intensification, yet Black representation in those studies is suboptimal.

methodsA multi-institutional, retrospective analysis of Black men with mHSPC was conducted, focusing on baseline demographics, treatment patterns, genomic profiles, clinical outcomes including prostate-specific antigen response, time to castrate-resistant prostate cancer (CRPC), and subsequent treatments.

resultsA total of 107 patients, median age 64 years, 62% with de novo metastases at diagnosis and 64% with high-volume disease, were included. Twenty-nine patients (27%) were treated with androgen deprivation therapy (ADT) with and without first generation anti-androgens, while 20%, 38% and 5% received chemotherapy, abiraterone, and enzalutamide, respectively. At time of data cut-off, 57 (54%) patients had developed CRPC, with a median time to CRPC of 25.4 months (95% CI 20.3-30.4). The median time to CRPC was 46.3 months (18.9-73.7) and 23.4 months (18.6-28.2) for patients who received ADT with or without first-generation anti-androgens and treatment intensification, respectively. The 2-year survival rate was 93.3%, and estimated median overall survival of was 74.9 months (95% CI, 68.7-81.0). Most patients (90%) underwent germline testing; the most frequent known alterations were found within the DNA repair group of genes. Somatic testing revealed pathogenic alterations of interest, notably TP53 (24%) and CDK12 (12%).

conclusionIn our cohort, Black men with mHSPC presented with a high proportion of de novo metastases and high-volume disease. Treatment outcomes were very favorable with ADT-based regimens. The genomic landscape suggests different molecular profile relative to White patients with potential therapeutic implications.

Indexed as

Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantAndrogen AntagonistsHormonesHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeAndrogen AntagonistsHormonesAfrican Americansandrogen deprivation therapyDNA sequence analysishealth care disparitiesprostatic neoplasmssteroid synthesis inhibitors

Identifiers

PMID35274720
PMCPMC8914485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.